Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic

12 Mar 2020

Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.

Funding Economy FInancial Collection Fund Concept — A $120m financing should enable Nurix to get two programs into clinical development

Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic

More from Financing

More from Business